<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180522039787N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-08-27</date_registration>
      <primary_sponsor>Shahid Rajae Cardiovascular and Research Center</primary_sponsor>
      <public_title>effect of albumin in pediatric surgery</public_title>
      <acronym></acronym>
      <scientific_title>Compare the effects of 5% albumin dose versus 2% in prime solution on fluid balance in heart surgery on congenital heart disease in newborn and infant</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-03-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/31595</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, a random block was used.
Random units are individual.
The randomization tool in this study is a random numbered table.
The size of each block is 5, Blinding description: In this study, after cardiac surgery, all specimens are under echocardiography to check for ascites and efusion, which the pediatric cardiologist, who is responsible for this task, is blind to the study. The respectable perfusionists and the relevant heart surgeon are also blind to the patients. Nurses also do not know how to share patients. But the main investigator who is responsible for recording data is not blind to the study.
After determining the placement of the sample in the control group or the intervention, we prepare a sample of the primer solution. Regarding the used oxygenator, the serum level used for primers is different. For each 100 cc of serum, 5 g of albumin in the intervention group and 2 g in the control group are used to reach the desired crop. It should be noted that perfusionists who prepare prime solution for the patient are blind to the study.</study_design>
      <phase>3</phase>
      <hc_freetext>congenital heart desease.</hc_freetext>
      <i_freetext>Intervention 1: The intervention group in this study is a patient with albumin concentration of 5% in prime solutions.First, the appropriate oxygenator is selected with the patient and is primed with a ringer serum. Corresponding to the amount of ringer serum used to reach 5% concentration of albumin in prime solution, 20% vial of albumin available in the hospital is used. The albumin has been used in 50cc vials at a concentration of 20% in the hospital. For example, if 200 cc of the ringer  is used for the oxygenator prime, 10 g of albumin is added to the prime solution to achieve a 5% concentration of albumin in the patient's prime solution. Only in prime solution and once using albumin, then the process of preparing the patient and the equipment continues to proceed. Intervention 2: Control group: The control group in this study is a patient with albumin concentration of 2% in prime solutions.First, the appropriate oxygenator is selected with the patient and is primed with a ringer serum. Corresponding to the amount of ringer serum used to reach 2% concentration of albumin in prime solution, 20% vial of albumin available in the hospital is used. The albumin has been used in 50cc vials at a concentration of 10% in the hospital. For example, if 200 cc of the ringer  is used for the oxygenator prime, 4 g of albumin is added to the prime solution to achieve a 5% concentration of albumin in the patient's prime solution. Only in prime solution and once using albumin, then the process of preparing the patient and the equipment continues to proceed.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Amirhosein Salehzade</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Rajae Heart Center.Valieasr Ave</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1995614331</zip>
        <telephone>+98 21 23921</telephone>
        <email>a.salehzade@rhc.ac.ir</email>
        <affiliation>Shahid Rajae Cardiovascular and Research Center</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Amirhosein Salehzade</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Rajae Heart Center.Valieasr Ave</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1995614331</zip>
        <telephone>+98 21 23921</telephone>
        <email>a.salehzade@rhc.ac.ir</email>
        <affiliation>Shahid Rajae Heart Center</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Parental satisfaction regarding participation in research project
Age 5 days to 2 years
Weight less than or equal to 10 kg
Patients candidated for open heart surgery
Congenital anomaly of the heart
Duration of cardiopulmonary bypass[ for at least one hour and maximum three hours</inclusion_criteria>
      <agemin>5 days</agemin>
      <agemax>2 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Deep hypothermia
low cardiac output
edema or ascites before surgery
Infection and inflammation known a week before surgery
emergency surgery
Not consenting parents to enter the trial</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Q25.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Patent ductus arteriosus</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The intervention group in this study is a patient with albumin concentration of 5% in prime solutions.First, the appropriate oxygenator is selected with the patient and is primed with a ringer serum. Corresponding to the amount of ringer serum used to reach 5% concentration of albumin in prime solution, 20% vial of albumin available in the hospital is used. The albumin has been used in 50cc vials at a concentration of 20% in the hospital. For example, if 200 cc of the ringer  is used for the oxygenator prime, 10 g of albumin is added to the prime solution to achieve a 5% concentration of albumin in the patient's prime solution. Only in prime solution and once using albumin, then the process of preparing the patient and the equipment continues to proceed.</i_keyword>
      <i_keyword>Control group: The control group in this study is a patient with albumin concentration of 2% in prime solutions.First, the appropriate oxygenator is selected with the patient and is primed with a ringer serum. Corresponding to the amount of ringer serum used to reach 2% concentration of albumin in prime solution, 20% vial of albumin available in the hospital is used. The albumin has been used in 50cc vials at a concentration of 10% in the hospital. For example, if 200 cc of the ringer  is used for the oxygenator prime, 4 g of albumin is added to the prime solution to achieve a 5% concentration of albumin in the patient's prime solution. Only in prime solution and once using albumin, then the process of preparing the patient and the equipment continues to proceed.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Albumin. Timepoint: At the beginning of the study (before the study started) - Immediately in the intensive care unit - 24 hours later in the intensive care unit. Method of measurement: Albumin Measuring Laboratory Kit.</prim_outcome>
      <prim_outcome>On fluid balance. Timepoint: At the beginning of the study (before the study started) - Immediately in the intensive care unit - 24 hours later in the intensive care unit. Method of measurement: Laboratory kit measuring body electrolytes.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Rajae Cardiovascular and Research Center</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-02-17</approval_date>
        <contact_name>Ethics Committee at Shahid Rajaee Cardiology Hospital of Tehran</contact_name>
        <contact_address>valiasr Ave. niayesh blvd. shahid rajae cardiovascular and research center tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
